This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Peptides & Oligonucleotides

The Future of the Oligonucleotide and Peptide Therapeutics Industry

Posted by on 04 August 2020
Share this article

In this second edition of the TIDES: Oligonucleotide and Peptide Therapeutics eBook Series, we explore the possible changes in the industry over the next decade. Where are the next goals for oligonucleotide and peptide-based drugs, and what events could be in store for the industry over the next few years?

Join us as we look in depth at survey responses from oligonucleotide and peptide therapeutics professionals around the world on areas such as medical breakthroughs, technology, regulations and diversity in the workplace. We also discuss the progress of macromolecular drugs with industry leaders and ask for their predictions on how the sector will have changed by the year 2030.

The ebook includes:

Click the image at the top of the page or here to explore the ebook.

Share this article